Molecular determinants for high-affinity block of human EAG potassium channels by antiarrhythmic agents

Molecular Pharmacology

Volumn 65, Issue 5, 2004, Pages 1120-1129

  Gessner, Guido ^a   Zacharias, Martin ^b   Bechstedt, Susanne ^a   Schönherr, Roland ^a   Heinemann, Stefan H ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b JACOBS UNIVERSITY BREMEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; AMINO ACID; ANTIARRHYTHMIC AGENT; CLOFILIUM; ETHYLHEPTYL[4 (4 NITROPHENYL)BUTYL]AMINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; QUINIDINE; TERFENADINE; TETRABUTYLAMMONIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONFORMATION; CONTROLLED STUDY; DRUG POTENCY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; KIDNEY CELL; MUTATION; NONHUMAN; OOCYTE; PRIORITY JOURNAL; XENOPUS LAEVIS;

AMINO ACID SEQUENCE; ANIMALS; CELLS, CULTURED; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; OOCYTES; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; QUATERNARY AMMONIUM COMPOUNDS; SEQUENCE HOMOLOGY, AMINO ACID; XENOPUS LAEVIS;

EID: 2142808323     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.65.5.1120     Document Type: Article

References (31)

1. + channels. J Membr Biol 182:1-15.
2. Case DA, Pearlman DA, Caldwell JW, Cheatham TE, Ross WS, Simmerling CL, Darden TA, Merz KM, Stanton RV, Cheng AL, et al. (1999) AMBER 6. University of California, San Francisco.
3. Chen J, Seebohm G, and Sanguinetti MC (2002) Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc Natl Acad Sci USA 99:12461-12466.
4. Choi KL, Mossman C, Aubé J, and Yellen G (1993) The internal quaternary ammonium receptor site of Shaker potassium channels. Neuron 10:533-541.
5. + conduction and selectivity. Science (Wash DC) 280:69-77.
6. + channel and its structural implications. Nature (Lond) 403:321-325.
7. Ekins S, Crumb WJ, Sarazan D, Wikel JH, and Wrighton SA (2002) Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J Pharmacol Exp Ther 301:427-434.
8. + channels. Circ Res 82:386-395.
9. + channels. Mol Pharmacol 60:1343-1348.
10. Gessner G and Heinemann SH (2003) Inhibition of hEAG1 and hERG1 potassium channels by clofilium and its tertiary analogue LY97241. Br J Pharmacol 138: 161-171.
11. Ho SN, Hunt HD, Horton RM, Pullen JK, and Paese LR (1989) Site-directed mutagenesis by overlap extension polymerase chain reaction. Gene 77:51-59.
12. Jiang Y, Lee A, Chen J, Cadene M, Chait BT, and MacKinnon R (2002) The open pore conformation of potassium channels. Nature (Lond) 417:523-526.
13. Ju M and Wray D (2002) Molecular identification and characterisation of the human eag2 potassium channel. FEBS Lett 524:204-210.
14. + channels by vesnarinone. Mol Pharmacol 60:244-253.
15. Keating MT and Sanguinetti MC (2001) Molecular and cellular mechanisms of cardiac arrhythmia. Cell 104:569-580.
16. Lees-Miller JP, Duan Y, Teng GQ, and Duff HJ (2000) Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: Involvement of S6 sites. Mol Pharmacol 57:367-374.
17. Madura JD, Briggs JM, Wade RC, Davis ME, Luty BA, Ilin A, Antosiewicz J, Gilson MK, Bagheri B, Scott LR, and McCammon JA (1995) Electrostatics and diffusion in solution: simulations with the University of Houston Brownian Dynamics program. Comput Phys Commun 91:57-95.
18. Malayev AA, Nelson DJ, and Philipson LH (1995) Mechanism of clofilium block of the human Kv1.5 delayed rectifier potassium channel. Mol Pharmacol 47:198-205.
19. Milnes JT, Crociani O, Arcangeli A, Hancox JC, and Witchel HJ (2003) Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol 139:887-898.
20. Mitcheson JS, Chen J, Lin M, Culberson C, and Sanguinetti MC (2000) A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 97:12329-12333.
21. Mitcheson JS (2003) Drug binding to HERG channels: evidence for a 'non-aromatic' binding site by fluvoxamine. Br J Pharmacol 139:883-884.
22. + channels. EMBO (Eur Mol Biol Organ J) J 18:5540-5547.
23. Paul AA, Witchel HJ, and Hancox JC (2002) Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br J Pharmacol 136:717-729.
24. + channel block. J Biol Chem 277:23587-23595.
25. Kr, potassium channel. Cell 81:299-307.
26. Schönherr R, Gessner G, Löber K, and Heinemann SH (2002) Functional distinction of human EAG1 and EAG2 potassium channels. FEBS Lett 514:204-208.
27. Schönherr R, Hehl S, Terlau H, Baumann A, and Heinemann SH (1999) Individual subunits contribute independently to slow gating of bovine EAG potassium channels. J Biol Chem 274:5362-5369.
28. Schönherr R and Heinemann SH (1996) Molecular determinants for activation and inactivation of HERG, a human inward rectifier potassium channel. J Physiol 493:635-642.
29. Steinberg MI and Molloy BB (1979) Clofilium - a new antifibrillatory agent that selectively increases cellular refractoriness. Life Sci 25:1397-1406.
30. Suessbrich H, Schönherr R, Heinemann SH, Lang F, and Busch AE (1997) Specific block of cloned Herg channels by clofilium and its tertiary analog LY97241. FEBS Lett 414:435-438.
31. Zhou M, Morais-Cabral JH, Mann S, and MacKinnon R (2001) Potassium channel receptor site for the inactivation gate and quaternary amine inhibitors. Nature (Lond) 411:657-661.